Ask AI
ProCE Banner Activity

Hitting the Target in Atopic Dermatitis: Interdisciplinary Team Training for Leveraging IL-13 Inhibitors to Address the Burden of Disease

Slideset

Expert-curated slides on the disease burden patients with moderate to severe atopic dermatitis face as well as the latest data on and strategies for integrating IL-13 inhibitors in your practice.

Released: October 03, 2025

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with Smart Patients.

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Partners

Smart Patients

ProCE Banner

Target Audience

This education is intended for dermatologists, allergists, pediatricians, primary care providers, pharmacists, nurse practitioners (NPs), and physician associates (PAs) who manage patients with moderate-to-severe atopic dermatitis.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate the therapeutic rationale for advanced therapies targeting IL-13 based on the pathophysiology of AD

  • Assess the clinical profile, safety, and efficacy of advanced therapies targeting IL-13 in moderate to severe AD

  • Recognize patient candidates for advanced biologic therapies targeting IL-13 in moderate to severe AD